JSPR Stock Price, Jasper Therapeutics, . Quote, Chart

Market Summary

USD22.26+0.34

Delayedas of 30 Apr 2024, 01:53 pm

1.55%

JSPR Stock Price

View Fullscreen

JSPR RSI Chart

JSPR Valuation

Market Cap

244.7M

Price/Earnings (Trailing)

-3.8

Price/Sales (Trailing)

13.79

EV/EBITDA

-84.91

Price/Free Cashflow

-4.7

JSPR Price/Sales (Trailing)

JSPR Profitability

Return on Equity

-82.18%

Return on Assets

-67.94%

Free Cashflow Yield

-21.29%

JSPR Fundamentals

JSPR Revenue

JSPR Earnings

Earnings (TTM)

-64.5M

Earnings Growth (Yr)

-25.51%

Earnings Growth (Qtr)

5.49%

Breaking Down JSPR Revenue

52 Week Range

22.50

(Low)(High)

Last 7 days

-3.0%

Last 30 days

-25.6%

Last 90 days

87.9%

Trailing 12 Months

64.2%

How does JSPR drawdown profile look like?

JSPR Financial Health

Current Ratio

7.19

JSPR Investor Care

Shares Dilution (1Y)

193.44%

Diluted EPS (TTM)

-6.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Jasper Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	mahal jeetinder singh	acquired	6,390	7.1	900	chief operating officer
Mar 12, 2024	mahal jeetinder singh	sold	-23,792	26.4358	-900	chief operating officer
Feb 08, 2024	carlyle group inc.	bought	2,460,500	12.95	190,000	-
Feb 08, 2024	velan capital investment management lp	bought	4,532,500	12.95	350,000	-
Nov 28, 2023	wiggans thomas g	bought	6,486	0.6486	10,000	-
Nov 21, 2023	wiggans thomas g	bought	6,383	0.6383	10,000	-
Nov 20, 2023	wiggans thomas g	bought	6,309	0.6309	10,000	-
Nov 17, 2023	wiggans thomas g	bought	5,966	0.5966	10,000	-
Nov 16, 2023	wiggans thomas g	bought	5,965	0.5965	10,000	-
Oct 13, 2023	lis william	sold	-6,776	0.8508	-7,965	-

Which funds bought or sold JSPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	110,000	110,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-34,395	-	-%
Apr 23, 2024	BFSG, LLC	new	-	294	294	-%
Apr 23, 2024	Summit Trail Advisors, LLC	sold off	-100	-51,285	-	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-	-	-%
Mar 18, 2024	KINGDON CAPITAL MANAGEMENT, L.L.C.	added	132	3,458,120	5,586,120	0.35%
Mar 11, 2024	VANGUARD GROUP INC	added	7.91	574,272	3,229,340	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	8,844	8,844	-%
Feb 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	reduced	-87.46	1,645,070	5,626,060	0.90%

Are Funds Buying or Selling JSPR?

Are funds buying JSPR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own JSPR

No. of Funds

Unveiling Jasper Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 27, 2024	avidity partners management lp	5.1%	760,000	SC 13G
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 14, 2024	qiming u.s. healthcare fund ii, l.p.	6.2%	928,964	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 12, 2024	carlyle group inc.	7.1%	1,066,189	SC 13D/A
Feb 09, 2024	velan capital investment management lp	7.9%	1,188,500	SC 13D/A
Feb 05, 2024	sphera funds management ltd.	6.39%	7,130,625	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	8.8%	987,096	SC 13G/A
Oct 10, 2023	sphera funds management ltd.	5.13%	5,687,134	SC 13G
Feb 27, 2023	velan capital investment management lp	7.7%	8,385,000	SC 13D

Recent SEC filings of Jasper Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Mar 27, 2024	SC 13G	Major Ownership Report
Mar 12, 2024	144	Notice of Insider Sale Intent
Mar 12, 2024	4	Insider Trading
Mar 06, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	10-K	Annual Report
Mar 05, 2024	S-8	Employee Benefits Plan
Mar 04, 2024	8-K	Current Report

Peers (Alternatives to Jasper Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Jasper Therapeutics, Inc. News

Latest updates

Jasper Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q2	2022Q1	2019Q4
Revenue	31.0%	1,436,000	1,096,000	92,000	-	-
Operating Expenses	27.8%	17,827,000	13,947,000	11,963,000	12,778,000	-
S&GA Expenses	9.4%	4,530,000	4,142,000	3,828,000	4,590,000	-
R&D Expenses	35.6%	13,297,000	9,805,000	8,135,000	8,188,000	-
Interest Expenses	-55.7%	-109,000	-70,000	-3,000	-74,000	-
EBT Margin	-	-	-	-	-	-3.75
Net Income	-12.8%	-16,080,000	-14,260,000	-10,404,000	-2,207,000	-595,380
Net Income Margin	100.0%	-	-11.35	-	-	-3.86
Free Cashflow	-28.4%	-13,272,000	-10,335,000	-9,356,000	-14,213,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	-14.1%	95.00	110	124	139	48.00	59.00	70.00	81.00	94.00	107	101	101	23.00	101	102	102	102
Current Assets	-15.5%	89.00	105	119	133	42.00	52.00	63.00	74.00	88.00	102	0.00	1.00	21.00	1.00	1.00	1.00	2.00
Cash Equivalents	-16.3%	87.00	104	116	129	38.00	51.00	61.00	71.00	85.00	101	17.00	24.00	20.00	15.00	1.00	1.00	27.00
Net PPE	-1.9%	3.00	3.00	3.00	3.00	4.00	4.00	4.00	3.00	4.00	3.00	3.00	-	1.00	-	-	-	-
Liabilities	1.1%	16.00	16.00	14.00	14.00	12.00	12.00	12.00	12.00	24.00	29.00	14.00	11.00	15.00	4.00	4.00	4.00	11.00
Current Liabilities	3.9%	12.00	12.00	9.00	8.00	7.00	7.00	7.00	6.00	8.00	9.00	0.00	0.00	4.00	0.00	0.00	0.00	0.00
Shareholder's Equity	-16.7%	78.00	94.00	110	125	36.00	48.00	59.00	68.00	70.00	79.00	5.00	2.00	0.00	5.00	5.00	5.00	5.00
Retained Earnings	-10.8%	-169	-153	-135	-119	-105	-91.92	-80.06	-69.66	-67.45	-58.39	-5.15	-1.58	-36.81	-0.44	-0.24	0.00	-0.60
Additional Paid-In Capital	0.4%	248	247	246	245	141	139	139	138	137	137	10.00	7.00	2.00	5.00	5.00	5.00	6.00
Shares Outstanding	0.7%	11.00	11.00	11.00	11.00	4.00	4.00	4.00	4.00	4.00	0.00	-	-	0.00	0.00	-	-	0.00
Float	-	-	-	111	-	-	-	49.00	-	-	-	99.00	-	-	-	103	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-37.6%	-16,500	-11,993	-13,272	-10,335	-12,688	-9,643	-9,356	-14,213	-14,584	-7,108	-5,791	-6,195	-5,393	-12,467	-173	-232	-
Share Based Compensation	-17.0%	1,158	1,395	1,391	1,267	1,604	644	1,065	778	231	195	295	327	437	316	-	-	-
Cashflow From Investing	-Infinity%	-230	-	-11.00	-26.00	-82.00	-222	-243	-29.00	-711	-470	-287	-960	18.00	72.00	31.00	77.00	-
Cashflow From Financing	-852.8%	-271	36.00	-305	101,511	28.00	1.00	13.00	13.00	-909	91,726	-600	10,752	10,803	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

JSPR Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 51,785	$ 34,627
General and administrative	17,076	16,569
Total operating expenses	68,861	51,196
Loss from operations	(68,861)	(51,196)
Interest income	5,199	701
Change in fair value of earnout liability	18	5,725
Change in fair value of common stock warrant liability	(575)	7,200
Other income (expense), net	(246)	(115)
Total other income, net	4,396	13,511
Net loss and comprehensive loss	$ (64,465)	$ (37,685)
Net loss per share attributable to common stockholders, basic (in Dollars per share)	$ (6.18)	$ (10.33)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares)	10,439,034	3,648,140

JSPR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 86,887	$ 38,250
Other receivables		663
Prepaid expenses and other current assets	2,051	2,818
Total current assets	88,938	41,731
Property and equipment, net	2,727	3,568
Operating lease right-of-use assets	1,467	1,886
Restricted cash	417	417
Other non-current assets	1,343	759
Total assets	94,892	48,361
Current liabilities:
Accounts payable	4,149	1,768
Current portion of operating lease liabilities	972	865
Accrued expenses and other current liabilities	7,253	4,432
Total current liabilities	12,374	7,065
Non-current portion of operating lease liabilities	1,814	2,786
Common stock warrant liability		150
Earnout liability		18
Other non-current liabilities	2,264	2,353
Total liabilities	16,452	12,372
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock: $0.0001 par value — 10,000,000 shares authorized at December 31, 2023 and 2022; none issued and outstanding at December 31, 2023 and 2022
Common stock: $0.0001 par value — 492,000,000 shares authorized at December 31, 2023 and 2022, respectively; 11,163,896 and 3,804,427 shares issued and outstanding at December 31, 2023 and 2022, respectively	1
Additional paid-in capital	248,039	141,124
Accumulated deficit	(169,600)	(105,135)
Total stockholders’ equity	78,440	35,989
Total liabilities and stockholders’ equity	$ 94,892	$ 48,361

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

CEO	Mr. Ronald A. Martell
WEBSITE	jaspertherapeutics.com/
INDUSTRY	Biotechnology
EMPLOYEES	35

Jasper Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Jasper Therapeutics, Inc.? What does JSPR stand for in stocks?

JSPR is the stock ticker symbol of Jasper Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jasper Therapeutics, Inc. (JSPR)?

As of Mon Apr 29 2024, market cap of Jasper Therapeutics, Inc. is 244.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JSPR stock?

You can check JSPR's fair value in chart for subscribers.

What is the fair value of JSPR stock?

You can check JSPR's fair value in chart for subscribers. The fair value of Jasper Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Jasper Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JSPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Jasper Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether JSPR is over valued or under valued. Whether Jasper Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Jasper Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JSPR.

What is Jasper Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, JSPR's PE ratio (Price to Earnings) is -3.8 and Price to Sales (PS) ratio is 13.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JSPR PE ratio will change depending on the future growth rate expectations of investors.